Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds.
Meanwhile, President Donald Trump offered U.K. Prime MInister Boris Johnson, in the ICU with COVID-19, unproven treatments. And news emerged that Trump himself holds a small financial interest in Sanofi, which makes an off-patent brand of hydroxychloroquine.
India is reportedly retracting export bans on 13 active pharmaceutical ingredients and finished formulations, and hydroxychloroquine may be included.
As of Tuesday, the number of global confirmed cases had surpassed 1.36 million, according to Johns Hopkins University’s real-time dashboard, and nearly 76,000 people had died.
See all of FiercePharma’s COVID-19 coverage here
By Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale
Source: Fierce Pharma
NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.
The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.
BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.
